Guoyong Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guoyong Yu has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Jun Qu
Department of General Surgery, Aerospace Center Hospital, Beijing, China
10 shared publications Nan Yao
Department of General Surgery, Aerospace Center Hospital, 15 Yuquan Road, Haidian District, Beijing, 100049, China
9 shared publicationsWenqiang Li
Department of General Surgery, Aerospace Center Hospital, 15 Yuquan Road, Haidian District, Beijing, 100049, China
9 shared publicationsNing Duan
Department of General Surgery, Aerospace Center Hospital, 15 Yuquan Road, Haidian District, Beijing, 100049, China
7 shared publicationsFuzhou Han
Department of General Surgery, Aerospace Center Hospital, 15 Yuquan Road, Haidian District, Beijing, 100049, China
6 shared publicationsGuoshuai Xu
Department of General Surgery, Aerospace Center Hospital, Beijing, China
4 shared publications
Latest Publications
- 24 May 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (11) , 4996-5009
Practical integration of ctDNA-defined minimal residual disease in gastrointestinal cancers: testing windows and evidence-aligned management frameworks
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of minimal or molecular residual disease and real-time tumor burden in gastrointestinal cancers, but its clinical integration remains uneven across disease settings. This narrative review summarizes current evidence in colorectal, gastroesophageal, pancreatic, and biliary cancers, with emphasis on practical testing windows, assay selection, and evidence-aligned interpretation. The strongest data support ctDNA use in resected colon cancer, particularly stage II disease, where postoperative ctDNA refines recurrence risk assessment and has enabled treatment de-escalation in selected prospective settings. In rectal, upper gastrointestinal, pancreatic, and biliary cancers, current evidence is mainly prognostic and less practice-defining. Serial ctDNA may support postoperative risk stratification, surveillance prioritization, and trial selection, but treatment escalation or de-escalation should preferably remain within prospectively studied contexts. Key barriers include assay standardization, false-positive calls, turnaround time, reimbursement, and the need to distinguish prognostic validity from proven clinical utility.
- 24 May 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (11) , 4996-5009
Practical integration of ctDNA-defined minimal residual disease in gastrointestinal cancers: testing windows and evidence-aligned management frameworks
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of minimal or molecular residual disease and real-time tumor burden in gastrointestinal cancers, but its clinical integration remains uneven across disease settings. This narrative review summarizes current evidence in colorectal, gastroesophageal, pancreatic, and biliary cancers, with emphasis on practical testing windows, assay selection, and evidence-aligned interpretation. The strongest data support ctDNA use in resected colon cancer, particularly stage II disease, where postoperative ctDNA refines recurrence risk assessment and has enabled treatment de-escalation in selected prospective settings. In rectal, upper gastrointestinal, pancreatic, and biliary cancers, current evidence is mainly prognostic and less practice-defining. Serial ctDNA may support postoperative risk stratification, surveillance prioritization, and trial selection, but treatment escalation or de-escalation should preferably remain within prospectively studied contexts. Key barriers include assay standardization, false-positive calls, turnaround time, reimbursement, and the need to distinguish prognostic validity from proven clinical utility.
- Open Access
- 22 April 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
The combined impact of social isolation and unhealthy risk score on mortality risk: a study from two prospective cohorts
Social isolation and health impacting factors (used to calculate a unhealth risk score) pose significant public health challenges globally. This study aims
- 22 April 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Open AccessThe combined impact of social isolation and unhealthy risk score on mortality risk: a study from two prospective cohorts
Social isolation and health impacting factors (used to calculate a unhealth risk score) pose significant public health challenges globally. This study aims
- Open Access
- 16 February 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1696331
Exploring the link between metabolic dysfunction-associated fatty liver disease and subclinical hypothyroidism in adolescents: a comprehensive review
Background/objectives: Metabolic dysfunction–associated fatty liver disease (MAFLD) and subclinical hypothyroidism (SCH) increasingly co-occur in adolescents, yet their inter-relationship and clinical relevance remain uncertain. Objective: To synthesize evidence on epidemiologic associations, shared mechanisms, and care implications linking MAFLD and SCH in youth. Methods: We conducted a structured review of PubMed, Embase, Web of Science, and the Cochrane Library from inception to December 31, 2024, focusing on pediatric observational studies and mechanistic or interventional data relevant to adolescents. Two reviewers screened studies and extracted design, diagnostics, exposures (TSH/thyroid hormones), outcomes (steatosis severity, fibrosis, liver enzymes), and adjusted effect estimates. Risk of bias was narratively assessed for observational designs. Results: Pediatric cohorts consistently report a positive association between higher TSH (within the reference or mildly elevated range) and hepatic steatosis severity, with several studies indicating a dose–response gradient. Mechanistic evidence suggests TSHR–SREBP-1c signaling, insulin resistance, adipokine imbalance, low-grade inflammation, and gut–liver–thyroid crosstalk as plausible pathways. Adult interventional data show that levothyroxine therapy for SCH can modestly reduce liver fat and aminotransferases; however, pediatric trials are lacking. Definitions, diagnostic modalities, and confounding control vary across studies, and most pediatric evidence is cross-sectional, limiting causal inference. Conclusions: In adolescents, MAFLD and SCH appear linked through metabolic and endocrine pathways, but causality remains unproven. Risk-based screening may be warranted—thyroid testing in MAFLD and targeted liver assessment in persistent SCH—while longitudinal cohorts and pediatric trials are needed to define thresholds for intervention and potential benefits of endocrine management.
- 16 February 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1696331
Open AccessExploring the link between metabolic dysfunction-associated fatty liver disease and subclinical hypothyroidism in adolescents: a comprehensive review
Background/objectives: Metabolic dysfunction–associated fatty liver disease (MAFLD) and subclinical hypothyroidism (SCH) increasingly co-occur in adolescents, yet their inter-relationship and clinical relevance remain uncertain. Objective: To synthesize evidence on epidemiologic associations, shared mechanisms, and care implications linking MAFLD and SCH in youth. Methods: We conducted a structured review of PubMed, Embase, Web of Science, and the Cochrane Library from inception to December 31, 2024, focusing on pediatric observational studies and mechanistic or interventional data relevant to adolescents. Two reviewers screened studies and extracted design, diagnostics, exposures (TSH/thyroid hormones), outcomes (steatosis severity, fibrosis, liver enzymes), and adjusted effect estimates. Risk of bias was narratively assessed for observational designs. Results: Pediatric cohorts consistently report a positive association between higher TSH (within the reference or mildly elevated range) and hepatic steatosis severity, with several studies indicating a dose–response gradient. Mechanistic evidence suggests TSHR–SREBP-1c signaling, insulin resistance, adipokine imbalance, low-grade inflammation, and gut–liver–thyroid crosstalk as plausible pathways. Adult interventional data show that levothyroxine therapy for SCH can modestly reduce liver fat and aminotransferases; however, pediatric trials are lacking. Definitions, diagnostic modalities, and confounding control vary across studies, and most pediatric evidence is cross-sectional, limiting causal inference. Conclusions: In adolescents, MAFLD and SCH appear linked through metabolic and endocrine pathways, but causality remains unproven. Risk-based screening may be warranted—thyroid testing in MAFLD and targeted liver assessment in persistent SCH—while longitudinal cohorts and pediatric trials are needed to define thresholds for intervention and potential benefits of endocrine management.
- Top Cited PapersOpen Access
- 10 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Biomarker guided combination strategies and perioperative integration for immune cold microsatellite stable colorectal cancer
Background: Most colorectal cancers (CRC) are microsatellite stable (MSS) and show little benefit from single-agent immune checkpoint inhibition (ICI). A rapidly expanding body of work now focuses on combination strategies to remodel the tumor microenvironment (TME) and convert immune-“cold” MSS disease into an immune-responsive state. Main body: We synthesize (i) biological liabilities that underpin MSS immune resistance; (ii) clinical evidence across key combination classes—anti-angiogenic/VEGFR + ICI (randomized AtezoTRIBE suggests a progression-free survival benefit when atezolizumab is added to FOLFOXIRI + bevacizumab), multikinase TKI + PD-1/PD-L1 (mixed activity and geographic/site heterogeneity; LEAP-017 was negative for overall survival), dual-checkpoint or next-generation CTLA-4 backbones (phase-1 botensilimab + balstilimab with durable responses in heavily pretreated MSS mCRC), EGFR- or HER2-targeted plus ICI (signals in molecularly defined subsets; e.g., CAVE rechallenge), and RT/ablation + ICI (biologically compelling but heterogeneous outcomes in pMMR-dominant settings). We emphasize biomarker-anchored selection—topology of disease (especially active liver metastases), inflammatory gene programs, and ctDNA kinetics—and propose peri-operative/oligometastatic integration frameworks relevant to surgical teams. Conclusions: Converting MSS CRC from cold to hot appears feasible in biologically selected contexts and with rational sequences. The next wave should stratify by liver involvement, embed ctDNA-anchored endpoints, and leverage surgery-embedded window studies to verify on-treatment immune conditioning.
- 10 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Top Cited PapersOpen AccessBiomarker guided combination strategies and perioperative integration for immune cold microsatellite stable colorectal cancer
Background: Most colorectal cancers (CRC) are microsatellite stable (MSS) and show little benefit from single-agent immune checkpoint inhibition (ICI). A rapidly expanding body of work now focuses on combination strategies to remodel the tumor microenvironment (TME) and convert immune-“cold” MSS disease into an immune-responsive state. Main body: We synthesize (i) biological liabilities that underpin MSS immune resistance; (ii) clinical evidence across key combination classes—anti-angiogenic/VEGFR + ICI (randomized AtezoTRIBE suggests a progression-free survival benefit when atezolizumab is added to FOLFOXIRI + bevacizumab), multikinase TKI + PD-1/PD-L1 (mixed activity and geographic/site heterogeneity; LEAP-017 was negative for overall survival), dual-checkpoint or next-generation CTLA-4 backbones (phase-1 botensilimab + balstilimab with durable responses in heavily pretreated MSS mCRC), EGFR- or HER2-targeted plus ICI (signals in molecularly defined subsets; e.g., CAVE rechallenge), and RT/ablation + ICI (biologically compelling but heterogeneous outcomes in pMMR-dominant settings). We emphasize biomarker-anchored selection—topology of disease (especially active liver metastases), inflammatory gene programs, and ctDNA kinetics—and propose peri-operative/oligometastatic integration frameworks relevant to surgical teams. Conclusions: Converting MSS CRC from cold to hot appears feasible in biologically selected contexts and with rational sequences. The next wave should stratify by liver involvement, embed ctDNA-anchored endpoints, and leverage surgery-embedded window studies to verify on-treatment immune conditioning.
- Open Access
- 24 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2155
Chemotherapy and age stratified survival outcomes in colorectal cancer based on a population analysis from the surveillance epidemiology and end results program 2010 to 2020
The role of chemotherapy in colorectal cancer (CRC) treatment, particularly in elderly and very young patients, remains controversial. This study aims to evaluate the survival benefits of chemotherapy across different age groups in CRC patients using real-world data. We conducted a prospective cohort study using data from the SEER database from 2010 to 2020. A total of 256,320 CRC patients were included in the final analysis. Chemotherapy status (yes/no) was the primary exposure. Outcomes included overall survival (OS), cause-specific survival, and cumulative incidence of cancer- and non-cancer-specific deaths. Statistical analyses involved multivariable Cox proportional hazards models, and competing risks models, adjusted for key demographic and clinical covariates. Chemotherapy significantly improved OS in patients aged 45 years and older, with the most substantial benefit in those aged 75-84 years (hazard ratios [HR] = 0.54, 95% confidence interval [CI] = 0.52-0.56) and ≥ 85 years (HR = 0.60, 95% CI = 0.57-0.64). Patients younger than 45 years did not show a significant survival benefit (HR = 1.02, 95% CI = 0.93-1.12). Survival benefit was consistent across tumor locations and most pronounced in stage III (HR = 0.40) and stage IV (HR = 0.39) disease. Competing risks models confirmed reduced cancer-specific mortality in older age groups. Sensitivity analyses excluding early deaths further validated the robustness of these findings. Chemotherapy conferred a survival benefit in patients aged ≥ 45 years, including the very elderly, when selection was based on functional status rather than age alone, whereas no clear benefit emerged in younger patients. This association persisted after multivariable adjustment and across stage-stratified and sensitivity analyses. Given SEER's lack of regimen, timing, comorbidity, and targeted-therapy detail, cautious interpretation is warranted.
- 24 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2155
Open AccessChemotherapy and age stratified survival outcomes in colorectal cancer based on a population analysis from the surveillance epidemiology and end results program 2010 to 2020
The role of chemotherapy in colorectal cancer (CRC) treatment, particularly in elderly and very young patients, remains controversial. This study aims to evaluate the survival benefits of chemotherapy across different age groups in CRC patients using real-world data. We conducted a prospective cohort study using data from the SEER database from 2010 to 2020. A total of 256,320 CRC patients were included in the final analysis. Chemotherapy status (yes/no) was the primary exposure. Outcomes included overall survival (OS), cause-specific survival, and cumulative incidence of cancer- and non-cancer-specific deaths. Statistical analyses involved multivariable Cox proportional hazards models, and competing risks models, adjusted for key demographic and clinical covariates. Chemotherapy significantly improved OS in patients aged 45 years and older, with the most substantial benefit in those aged 75-84 years (hazard ratios [HR] = 0.54, 95% confidence interval [CI] = 0.52-0.56) and ≥ 85 years (HR = 0.60, 95% CI = 0.57-0.64). Patients younger than 45 years did not show a significant survival benefit (HR = 1.02, 95% CI = 0.93-1.12). Survival benefit was consistent across tumor locations and most pronounced in stage III (HR = 0.40) and stage IV (HR = 0.39) disease. Competing risks models confirmed reduced cancer-specific mortality in older age groups. Sensitivity analyses excluding early deaths further validated the robustness of these findings. Chemotherapy conferred a survival benefit in patients aged ≥ 45 years, including the very elderly, when selection was based on functional status rather than age alone, whereas no clear benefit emerged in younger patients. This association persisted after multivariable adjustment and across stage-stratified and sensitivity analyses. Given SEER's lack of regimen, timing, comorbidity, and targeted-therapy detail, cautious interpretation is warranted.
- Open Access
- 8 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0332584
Relationship between weekends catch-up sleep and risk of aging
Background: Sleep has been proven to be associated with various chronic diseases and aging. However, many individuals fail to achieve recommended sleep durations on weekdays and opt for compensatory sleep during weekends. This study aims to investigate the relationship between weekend catch-up sleep (CUS) and aging. Methods: All participants were sourced from NHANES 2017–2018. Using the sleep questionnaire, we obtained participants’ sleep timings and durations on weekdays and weekends. Weekend CUS was identified as an extension in average weekend sleep duration. Biological age is a biomarker for evaluating biological aging, and its difference from actual age is used to determine aging. Weighted logistic regression analysis was employed to explore the relationship between CUS and aging. Results: A total of 4,713 participants were included in this study, with an average age of 47.54 ± 16.94 years. 50.6% of individuals experienced CUS. Compared to individuals without CUS, participants with CUS had a 20% lower risk of aging (OR = 0.80, 95% CI: 0.63−1). Specifically, participants who engaged in CUS for 0−1 hour showed a 23% lower risk of aging (OR = 0.77, 95% CI: 0.61–0.96), and those with CUS for 1−2 hours had a 20% lower risk of aging (OR = 0.80, 95% CI: 0.65–0.98). Stratifying by bedtime, the relationship between CUS and reduced aging risk is only observed in individuals who usually go to sleep before midnight and have CUS less than 2 hours. Conclusion: The 0–2 hour CUS is associated with a reduced risk of aging, and this relationship is more significant in participants who go to bed early and have healthy sleep patterns.
- 8 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0332584
Open AccessRelationship between weekends catch-up sleep and risk of aging
Background: Sleep has been proven to be associated with various chronic diseases and aging. However, many individuals fail to achieve recommended sleep durations on weekdays and opt for compensatory sleep during weekends. This study aims to investigate the relationship between weekend catch-up sleep (CUS) and aging. Methods: All participants were sourced from NHANES 2017–2018. Using the sleep questionnaire, we obtained participants’ sleep timings and durations on weekdays and weekends. Weekend CUS was identified as an extension in average weekend sleep duration. Biological age is a biomarker for evaluating biological aging, and its difference from actual age is used to determine aging. Weighted logistic regression analysis was employed to explore the relationship between CUS and aging. Results: A total of 4,713 participants were included in this study, with an average age of 47.54 ± 16.94 years. 50.6% of individuals experienced CUS. Compared to individuals without CUS, participants with CUS had a 20% lower risk of aging (OR = 0.80, 95% CI: 0.63−1). Specifically, participants who engaged in CUS for 0−1 hour showed a 23% lower risk of aging (OR = 0.77, 95% CI: 0.61–0.96), and those with CUS for 1−2 hours had a 20% lower risk of aging (OR = 0.80, 95% CI: 0.65–0.98). Stratifying by bedtime, the relationship between CUS and reduced aging risk is only observed in individuals who usually go to sleep before midnight and have CUS less than 2 hours. Conclusion: The 0–2 hour CUS is associated with a reduced risk of aging, and this relationship is more significant in participants who go to bed early and have healthy sleep patterns.
- Open Access
- 23 June 2025
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (6) , e70078
Relationship Between Salt Intake and Cardiovascular Disease
Cardiovascular disease (CVD) is a predominant global health issue, with dietary salt intake recognized as a crucial modifiable risk factor. This review elucidates the multifaceted relationship between salt consumption and CVD, exploring both its direct and indirect effects. While early research emphasized salt's influence on blood pressure, contemporary studies highlight the combined effects of dietary habits and genetic factors on CVD risk. The paper underscores the complex biological mechanisms linking high salt intake to CVD, including its impact on blood pressure, direct cardiovascular effects, immune responses, the role of prostanoids, epigenetic changes, and gut microbiome. Additionally, the review delves into the concept of salt sensitivity and its genetic underpinnings, emphasizing the heightened CVD risk in salt‐sensitive individuals. The potential benefits and challenges of salt substitutes are also discussed. Drawing from various study designs, including epidemiological studies and randomized controlled trials, the review provides a comprehensive understanding of the detrimental effects of excessive salt intake on cardiovascular health, emphasizing the need for refined dietary guidelines and targeted interventions.
- 23 June 2025
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (6) , e70078
Open AccessRelationship Between Salt Intake and Cardiovascular Disease
Cardiovascular disease (CVD) is a predominant global health issue, with dietary salt intake recognized as a crucial modifiable risk factor. This review elucidates the multifaceted relationship between salt consumption and CVD, exploring both its direct and indirect effects. While early research emphasized salt's influence on blood pressure, contemporary studies highlight the combined effects of dietary habits and genetic factors on CVD risk. The paper underscores the complex biological mechanisms linking high salt intake to CVD, including its impact on blood pressure, direct cardiovascular effects, immune responses, the role of prostanoids, epigenetic changes, and gut microbiome. Additionally, the review delves into the concept of salt sensitivity and its genetic underpinnings, emphasizing the heightened CVD risk in salt‐sensitive individuals. The potential benefits and challenges of salt substitutes are also discussed. Drawing from various study designs, including epidemiological studies and randomized controlled trials, the review provides a comprehensive understanding of the detrimental effects of excessive salt intake on cardiovascular health, emphasizing the need for refined dietary guidelines and targeted interventions.
- Open Access
- 3 May 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Identification and validation of susceptibility modules and hub genes of adrenocortical carcinoma through WGCNA and machine learning
Purpose Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy characterized by rapid progression, significantly impacting patients’ quality of life. Analyzing gene co-expression modules offers valuable insights into the molecular mechanisms driving ACC progression. In this study, we applied Weighted Gene Co-Expression Network Analysis (WGCNA) to identify gene co-expression modules associated with ACC progression. Methods Before conducting WGCNA, differential gene expression and immune infiltration analyses were performed on the GSE90713 dataset (available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi). Dynamic tree cutting was utilized to identify co-expression modules, which were subsequently analyzed to determine their correlations and associations with traits. A total of 21 co-expression modules were identified, with the yellow module demonstrating a strong correlation with the progression of ACC. Enrichment analysis was carried out on differentially expressed genes, the yellow module, cross-module interactions, and the final hub genes to identify the associated Biological Processes (BPs) and pathways relevant to ACC. Additionally, the CIBERSORT algorithm was employed to predict immune cell infiltration in ACC. Results The enrichment analysis revealed that pathways associated with cell division, protein synthesis, and metabolism play significant roles in the progression of ACC. Additionally, CDK1, AURKA, CCNB2, BIRC5, CCNB1, TYMS, and TOP2A were identified as key regulatory hub genes. Survival analysis further demonstrated that elevated expression levels of these genes in ACC tissues are significantly correlated with lower overall survival rates in patients, underscoring their critical involvement in ACC development and progression. Conclusion This study sheds light on the mechanisms underlying ACC progression and highlights potential therapeutic targets. By identifying specific immune cell subtypes associated with ACC, the findings may aid in developing immune modulation therapies aimed at preventing or treating ACC.
- 3 May 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Open AccessIdentification and validation of susceptibility modules and hub genes of adrenocortical carcinoma through WGCNA and machine learning
Purpose Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy characterized by rapid progression, significantly impacting patients’ quality of life. Analyzing gene co-expression modules offers valuable insights into the molecular mechanisms driving ACC progression. In this study, we applied Weighted Gene Co-Expression Network Analysis (WGCNA) to identify gene co-expression modules associated with ACC progression. Methods Before conducting WGCNA, differential gene expression and immune infiltration analyses were performed on the GSE90713 dataset (available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi). Dynamic tree cutting was utilized to identify co-expression modules, which were subsequently analyzed to determine their correlations and associations with traits. A total of 21 co-expression modules were identified, with the yellow module demonstrating a strong correlation with the progression of ACC. Enrichment analysis was carried out on differentially expressed genes, the yellow module, cross-module interactions, and the final hub genes to identify the associated Biological Processes (BPs) and pathways relevant to ACC. Additionally, the CIBERSORT algorithm was employed to predict immune cell infiltration in ACC. Results The enrichment analysis revealed that pathways associated with cell division, protein synthesis, and metabolism play significant roles in the progression of ACC. Additionally, CDK1, AURKA, CCNB2, BIRC5, CCNB1, TYMS, and TOP2A were identified as key regulatory hub genes. Survival analysis further demonstrated that elevated expression levels of these genes in ACC tissues are significantly correlated with lower overall survival rates in patients, underscoring their critical involvement in ACC development and progression. Conclusion This study sheds light on the mechanisms underlying ACC progression and highlights potential therapeutic targets. By identifying specific immune cell subtypes associated with ACC, the findings may aid in developing immune modulation therapies aimed at preventing or treating ACC.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Mind–Body Interventions for Prediabetes Management: Traditional Chinese Exercise and Its Dual Effects on Metabolic Control and Psychological Well‐Being—A Systematic Review and Meta‐Analysis
Aims: This study was aimed at evaluating the effectiveness of traditional Chinese exercises (TCEs) in improving both physical and psychological health in individuals with prediabetes. Methods: Randomized controlled trials were systematically searched in the Cochrane Library, PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and the Chinese Biomedical Literature Database (CBM) up to August 28, 2025. Data from 22 trials involving 1854 participants were analyzed using Stata 15.0. The risk of bias was assessed with the Cochrane RoB 2.0 tool. Results: TCEs significantly improved fasting blood glucose (FBG), insulin resistance, glycated hemoglobin (HbA1c), 2‐h postprandial blood glucose (2hPG), and several psychological outcomes compared with controls. Subgroup analyses showed consistent improvements in FBG at 3, 6, and 12 months, although the effect size and heterogeneity varied across time points. HbA1c and 2hPG improved at 3 and 6 months, while fasting insulin changes were significant only at 3 months. Baduanjin and Qigong were most effective for metabolic outcomes, whereas evidence for Taiji was limited and inconclusive, though some studies suggested potential benefits for HbA1c. Psychological benefits were observed across all exercise types. Conclusion: TCEs may enhance metabolic regulation and psychological well‐being in individuals with prediabetes, potentially reducing the risk of progression to Type 2 diabetes. However, due to high heterogeneity and small sample sizes for some outcomes, these findings should be interpreted with caution. Large, well‐designed multicenter trials are warranted to confirm these effects.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Open AccessMind–Body Interventions for Prediabetes Management: Traditional Chinese Exercise and Its Dual Effects on Metabolic Control and Psychological Well‐Being—A Systematic Review and Meta‐Analysis
Aims: This study was aimed at evaluating the effectiveness of traditional Chinese exercises (TCEs) in improving both physical and psychological health in individuals with prediabetes. Methods: Randomized controlled trials were systematically searched in the Cochrane Library, PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and the Chinese Biomedical Literature Database (CBM) up to August 28, 2025. Data from 22 trials involving 1854 participants were analyzed using Stata 15.0. The risk of bias was assessed with the Cochrane RoB 2.0 tool. Results: TCEs significantly improved fasting blood glucose (FBG), insulin resistance, glycated hemoglobin (HbA1c), 2‐h postprandial blood glucose (2hPG), and several psychological outcomes compared with controls. Subgroup analyses showed consistent improvements in FBG at 3, 6, and 12 months, although the effect size and heterogeneity varied across time points. HbA1c and 2hPG improved at 3 and 6 months, while fasting insulin changes were significant only at 3 months. Baduanjin and Qigong were most effective for metabolic outcomes, whereas evidence for Taiji was limited and inconclusive, though some studies suggested potential benefits for HbA1c. Psychological benefits were observed across all exercise types. Conclusion: TCEs may enhance metabolic regulation and psychological well‐being in individuals with prediabetes, potentially reducing the risk of progression to Type 2 diabetes. However, due to high heterogeneity and small sample sizes for some outcomes, these findings should be interpreted with caution. Large, well‐designed multicenter trials are warranted to confirm these effects.